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ABSTRACT   
Mutations in TANK binding kinase gene (TBK1) have been identified as causative in amyotrophic lateral 
sclerosis (ALS). Here, we examine the spectrum of TBK1 mutations in a cohort of ALS patients from 
Northern England, comparing missense and loss of function mutations with clinical phenotype. 
Analysis of 290 ALS cases identified seven variants, including one novel in-frame deletion (p.Ile85del). 
In silico analysis and review of the literature suggested that four variants, one nonsense mutation 
(p.Glu2Ter), two in-frame deletions (p.Ile85del, p.Glu643del) and one missense mutation 
(p.Gln565Pro) were pathogenic, whilst the remaining three missense mutations were variants of 
uncertain significance or benign. Post-mortem material was available from the patient with the novel 
in-frame deletion. Neuropathological examination established this individual had classical ALS 
pathology, with moderate phosphorylated TDP-43 neuronal and glial cytoplasmic inclusions in the 
motor cortex, skein-like inclusions in the lower motor ﾐW┌ヴﾗﾐゲ ;ﾐS さヮヴW-ｷﾐIﾉ┌ゲｷﾗﾐゲざ ｷﾐ デｴW ﾏWS┌ﾉﾉ;く 
This corresponds to Type B FTLD-TDP pathology and is consistent with previously published literature 
on TBK1 mutants. In addition to demonstrating no changes in TBK1 staining, we are the first to show 
there was no differential expression of interferon regulatory factor IRF3, a downstream effector of 
TBK1 in the innate immunity pathway, in the TBK1-mutant tissue compared to controls. Comparison 
of clinical and neuropathological data, however, suggests that TBK1-ALS cases show classical ALS 




ALS = amyotrophic lateral sclerosis 
bv-FTD = behavioural variant FTD 
C9ORF72 = chromosome 9 open reading frame 72 
EMG = electromyography 
FALS = familial ALS 
FTD = frontotemporal dementia 
FTLD-TDP = frontotemporal lobar degeneration with TDP-43 pathology 
IKK = IkB kinase 
IRF3/7 = interferon regulator factor 3/7 
LoF = loss of function 
OPTN = optineurin 
PPA = primary progressive aphasia 
SALS = sporadic ALS 
SOD1 = Cu/Zn superoxide dismutate 1 
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SQSTM1 = sequestosome/p62 
TARDBP = TAR DNA binding protein 
TBK1 = TANK binding kinase gene 
TDP-43 = 43kDa protein product of TARDBP gene 
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INTRODUCTION 
Amyotrophic lateral sclerosis (ALS) is an adult onset, progressive neurodegenerative disease, 
characterised by the loss of both upper and lower motor neurons. Although the majority of ALS cases 
are sporadic (SALS), approximately 10% are familial (FALS) and the most common genetic causes are 
mutations in C9ORF72, SOD1, TARDBP and FUS genes (1). However, it is becoming apparent that 
mutations in the 27 genes currently associated with FALS may also be present in apparently sporadic 
cases. In addition, there is evidence of mutations in several of these genes being associated with both 
ALS and frontotemporal dementia (FTD), termed ALS-FTD (1). ALS is a heterogeneous disease with the 
site of initial clinical presentation, disease progression rates, and involvement of cognitive and 
behavioural impairment showing variation between individuals (2). A wide range of survival times and 
age of disease onset are observed, even in individual members of families with the same pathogenic 
mutation (3). 
 
Mutations in TANK binding kinase gene (TBK1) located on chromosome 12 (12q14.2), were first linked 
to ALS in 2015 (4, 5). To date, multiple loss-of-function (LoF) and missense TBK1 variants have been 
reported and the majority of these are associated with either ALS, ALS-FTD or FTD (6-13). However, 
mutations in TBK1 have also been identified in cases of progressive bulbar palsy, primary progressive 
aphasia, monoparesis, progressive supranuclear palsy-like and cerebellar syndromes, as well as in 
I;ゲWゲ ﾗa W;ヴﾉ┞ ﾗﾐゲWデ Aﾉ┣ｴWｷﾏWヴげゲ SｷゲW;ゲW ;ﾐS ┌ﾐゲヮWIｷaｷWS SWﾏWﾐデｷ; (5, 9, 14, 15).  
 
Mutations altering splice-sites, in-frame deletions, frameshifts, and LoF variants show definite or 
probable pathogenicity, whilst the pathogenicity of missense variants are less certain. However, 
recently, Cui and colleagues showed that there is a significantly increased risk for ALS/FTD disease in 
individuals with LoF (Odds Ratio 11.78) and a moderately increased susceptibility for those carrying 
missense mutations (Odds Ratio 1.62) (16). In addition, de Majo and colleagues demonstrated that 
missense TBK1 mutations in functional domains impair the binding and phosphorylation of its target 
proteins, thereby causing a loss of function similar to that seen with truncation mutations (17).  
 
The TBK1 protein is a ubiquitously expressed serine-threonine kinase belonging to the IbK kinase (IKK) 
family, which is normally located in the cytoplasm. It is a key regulator of innate immunity signalling 
pathways. Following activation, TBK1 dimers phosphorylate interferon regulatory factors IRF3 and 
IRF7, which subsequently form homodimers and translocate to the nucleus, where they act as 
transcription factors for type 1 interferons (18). TBK1 also plays a role in autophagy and mitophagy, 
through phosphorylation of adaptor proteins such as optineurin (OPTN), p62/sequestosome (SQSTM) 
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and nuclear dot protein 25 (NDP25), which act by binding ubiquitinated proteins and mitochondria 
and enhancing their binding to the autophagosome protein LC3-II (18). Interestingly, mutations in 
OPTN and SQSTM1 have also been associated with ALS (19, 20).  
 
Correlations between clinical features and TBK1 mutations have not been fully elucidated. However, 
one study reported a later age of onset for TBK1-mutation carrying FTD patients (7). To explore the 
relationship between TBK1 mutations and disease phenotype, the aims of this study were to screen 
our cohort of ALS patients for mutations in TBK1 and to correlate LoF and missense variants with 
clinical and neuropathological features of ALS. Comparison of clinical and neuropathological data, 
however, did not establish any specific genotype/phenotype correlations within this cohort of TBK1-
ALS cases. 
 
MATERIALS AND METHODS 
 
Genomic DNA was extracted from 290 unrelated ALS cases, sourced from post-mortem cerebellum 
tissue (n=111) or whole blood samples (n=179), using the Promega Maxwell RSC system (Wisconsin, 
U“Aぶが ;ゲ ヮWヴ ﾏ;ﾐ┌a;Iデ┌ヴWヴげゲ ｷﾐゲデヴ┌Iデｷﾗﾐゲく AL“ I;ゲWゲ ;ﾉﾉ ｴ;S SWaｷﾐｷデW ﾗヴ ヮヴﾗH;HﾉW AL“ ;ゲ SWaｷﾐWS H┞ デｴW 
El Escorial criteria. The South Sheffield Research Ethics Committee approved the study (12/YH/0330) 
and informed consent was obtained from those participants who donated a blood sample. The use of 
post-mortem tissue in the study was reviewed by the Sheffield Brain Tissue Bank (SBTB) Management 
Board and approval to release tissue was granted under REC 08/MRE00/103. 
 
The TBK1 gene is comprised of 21 exons, 20 of which are coding, and these were amplified using 
polymerase chain reaction (PCR) in a thermal cycler (G-Storm, Somerton, UK). Primers for TBK1 exons 
2, 4, 5, 6, 7, 8, 9, 10, 11, 16, 17-18, 19-20, and 21 were those described previously (21). Primers for 
TBK1 exons 3, 12, 13, and 14-15 were re-designed using Primer Blast (NCBI; Supplementary Table 1). 
All primers were purchased from Eurofins Genomics (Ebersburg, Germany). 
 
PCR exon amplification was confirmed using gel electrophoresis, and products purified by treatment 
with Exonuclease 1 (NEB) and Shrimp Alkaline Phosphatase (ThermoFisher). Samples were sequenced 
using BigDye v3.1 (ThermoFisher) according to standard protocols and run on an Applied Biosystems 
3730 DNA analyser at the University of Sheffield Genetics Core Facility. The chromatograms were 
analysed using Geneious 9.1.5 (22). Sequences were aligned by Multiple Sequence Comparison by Log-
Expectation and referenced to the Ensembl transcript ENST00000331710.5 from the Ensembl GRCh37 
database. When potential mutations were found following alignment and comparison to the 
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reference genome, these were confirmed in a second PCR followed by sequencing with both forward 
and reverse primers.  
 
All variants were compared to those reported in the literature and in online databases (GnomAD, 
ExAC, ClinVar, Project Mine Data Browser に all accessed 20 February 2019). Variant effect on protein 
structure and function were predicted using Mutation Taster (23), which uses a Bayes classifier to 
predict the effect of a change having been trained on a set of >390,000 known mutations associated 
with disease and over 6 million non-pathogenic variants. PolyPhen-2 (24) and SIFT (25) were used 
;SSｷデｷﾗﾐ;ﾉﾉ┞ aﾗヴ ;ﾏｷﾐﾗ ;IｷS ゲ┌Hゲデｷデ┌デｷﾗﾐ ;ﾐ;ﾉ┞ゲWゲく M┌デ;デｷﾗﾐ T;ゲデWヴ ヴWゲ┌ﾉデゲ ﾗa けSｷゲW;ゲW I;┌ゲｷﾐｪげが “IFT 
values <0.05 and PolyPhen-ヲ ヴWゲ┌ﾉデゲ ﾗa けヮヴﾗH;Hﾉ┞ S;ﾏ;ｪｷﾐｪげが ﾗヴ けヮﾗゲゲｷHﾉ┞ S;ﾏ;ｪｷﾐｪげ ┘WヴW W┝ヮWIデWS デﾗ 
be pathogenic. Additionally, potential splice site mutations were analysed using Human Splice Finder 
(26). Finally, PyMol (https://www.pymol.org/Schrödinger) was used to visualise variant effects on 
protein structure. 
 
Post-mortem material was available from a patient with the p.Ile85del in-frame deletion of TBK1 (Case 
2). Representative blocks of brain, spinal cord and skeletal muscle were taken and fixed in formalin. 
Blocks were then embedded in paraffin wax, sectioned and stained for haematoxylin and eosin. 
Immunohistochemistry (IHC) for phosphorylated TDP-43, tau, CD68, TBK1 and IRF3 was performed 
(Table 1) using standard protocols (27, 28).  Immunohistochemistry for TBK1 and IRF3 was performed 




Variant screening of the 20 coding exons of TBK1 identified 22 variants in 290 samples in our cohort 
of ALS cases (Table 2; Supplementary Table 2). Seven variants (one nonsense, two-in-frame deletions, 
and four missense variants) were predicted to cause amino acid changes in the TBK1 protein. Of these, 
further analysis predicted four variants to be pathogenic, including a novel mutation in exon 4 (Table 
2; Figure 1). The remaining 15 variants comprised of 12 non-coding and 3 synonymous variants 
(Supplementary Table 2). 
 
Functional implications of predicted pathogenic mutations 
A nonsense mutation was detected in Case 1 within exon 2. The c.4C>T substitution resulted in a stop 
codon at the second amino acid, p.Glu2Ter. Pathogenicity was predicted by Mutation Taster as 
さSｷゲW;ゲW I;┌ゲｷﾐｪざ ;ﾐS デｴW ┗;ヴｷ;ﾐデ ｴ;ゲ HWWﾐ ヴWヮﾗヴデWS ヮヴW┗ｷﾗ┌ゲﾉ┞ ｷﾐ AL“ I;ゲWゲ (4, 13, 17).  
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Two in-frame-deletions were detected in Cases 2 and 3. Case 2 carried a novel 3bp deletion, c.253-
255delATT, in exon 4, which results in the deletion of isoleucine at amino acid 85, p.Ile85del (Figure 
2). This residue is located within the kinase domain and is likely to be pathogenic, as predicted by 
M┌デ;デｷﾗﾐ T;ゲデWヴ ;ゲ さSｷゲW;ゲW I;┌ゲｷﾐｪざく C;ゲW ン I;ヴヴｷWS デｴW ゲWIﾗﾐS ｷﾐ-frame-deletion c.1928-
1930delGAA, found in exon 18, which results in the deletion of a glutamic acid, p.Glu643del, within 
the coiled coil domain 1, involved in dimerization of TBK1 (Supplementary Figure 1). This variant is 
also predicted to be pathogenic, according to Mutation Taster, (disease causing) and has been 
reported previously in ALS (4, 5, 13).  
 
In Case 4, a previously reported missense variant was detected at c.1694A>C in exon 15, which causes 
a glutamine to a proline substitution at amino acid 565, p.Glu565Pro. This mutation is predicted to be 
さSｷゲW;ゲW I;┌ゲｷﾐｪざ H┞ M┌デ;デｷﾗﾐ T;ゲデWヴ ;ﾐS ;ゲ さヮヴﾗH;Hﾉ┞ S;ﾏ;ｪｷﾐｪざ ふヰくΓΓヰぶ H┞ Pﾗﾉ┞PｴWﾐ ;ﾐS 
さSWﾉWデWヴｷﾗ┌ゲざ H┞ “IFT ふヰくヰヰぶく P┞ﾏﾗﾉ ゲデヴ┌Iデ┌ヴ;ﾉ ;ﾐ;ﾉ┞ゲｷゲ ゲｴﾗ┘WS ; ヴWゲ┌ﾉデ;ﾐデ ヮヴﾗデWｷﾐ Iｴ;ﾐｪW ｷﾐ デｴW IﾗｷﾉWS 
coil domain 1, which is responsible for TBK1 protein dimerization (Supplementary Figure 2). 
 
As shown in Table 2, the remaining three missense variants (p.Lys291Glu, p.His322Tyr, p.Val464Ala) 
have been found in controls as well as in ALS cases, though the pathogenicity of these is less clear. 
Mutation Taster predicts they are aﾉﾉ さSｷゲW;ゲW I;┌ゲｷﾐｪざく TｴW ヮくL┞ゲヲΓヱGﾉ┌ ｷゲ SWゲIヴｷHWS ｷﾐ CﾉｷﾐV;ヴ ;ゲ ; 
variant of uncertain significance and it has been found more frequently in ALS than in controls 
according to the Project MinE Data Browser, based on 4,366 ALS cases and 1,832 controls (29). The 
p.His322Tyr variant has contradictory evidence, as it has been reported in ExAC and gnomAD and 
could therefore be considered benign, however, none of these variants have been detected in the 
controls in Project MinE, therefore labelling these as variants of unknown significance may be more 
appropriate. In contrast, the p.Val464Ala variant has been reported in both cases and controls in 
Project MinE and both PolyPhen and ClinVar consider it as benign. 
 
Clinical phenotypes associated with TBK1 mutations 
The clinical features of the four cases who carry the predicted pathogenic mutations in TBK1 are 
described below and summarised in Table 3. 
 
Case 1: The p.Glu2Ter nonsense mutation was detected in a male patient who developed ALS at 46 
years of age with unilateral lower limb onset. There was no family history of ALS but a maternal 
grandmother had an unspecified dementia. Electromyography (EMG) demonstrated reinnervation 
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and chronic denervation, but no active denervation, and MRI of the head was normal, with spinal MRI 
showing disc protrusion without cord compromise. Progression manifested as bilateral leg spasticity 
and arm involvement, followed by a mild depression, which did not require treatment. Mild 
breathlessness was noted later. There was no evidence of cognitive change and disease progressed 
relatively slowly with the patient alive 7.75 years after diagnosis. 
 
Case 2: The novel in frame deletion in exon 4, p.Ile85del, was detected in a female with ALS and no 
family history.  She presented at age 59 with lower limb onset disease which progressed to affect her 
upper limbs and bulbar function, which subsequently led to a gastrostomy.  Involvement of her 
respiratory muscles led to her death, four years and nine months after onset. EMG showed signs of 
widespread active and chronic denervation and reinnervation. There were no signs of cognitive 
Iｴ;ﾐｪWが デｴﾗ┌ｪｴ デｴWヴW ┘;ゲ ; ｴｷゲデﾗヴ┞ ﾗa BWｴNWデげゲ SｷゲW;ゲW ;ﾐS SWヮヴWゲゲｷﾗﾐく  
 
Case 3: The p.Glu643del in frame deletion in exon 18 was found in a male whose father had limb onset 
ALS. He presented with word finding difficulties and slow speech at 61 years of age. Three years later, 
bulbar symptoms progressed and upper limb and neck weakness emerged with dysphagia. EMG was 
consistent with the clinical diagnosis of ALS. The patient also experienced irritability and emotional 
lability and neuropsychological testing showed cognitive impairment in the form of slowed 
information processing. Disease-typical deterioration occurred over the following year resulting in 
death at age 66. 
 
Case 4: The p.Gln565Pro missense variant was found in a female, whose brother had also died of ALS. 
She presented with limb onset disease at 51 years of age. Disease was characterised as an upper motor 
neuron predominant/PLS phenotype. Bulbar compromise after a year culminated in the insertion of a 
gastrostomy tube. EMG revealed widespread but patchy neurogenic changes with spontaneous 
activity in three muscles, which supported the diagnosis. MRI of the brain showed numerous, non-
specific, high-signal foci within the white matter of both hemispheres, in a peripheral distribution, as 
well as in the pons. The patient also had depression and emotional lability. She had severe spasticity, 
despite appropriate baclofen prescription, notably in the jaw resulting in oral ulcers. Respiratory 
failure occurred 3 years after diagnosis resulting in death 4 years after symptom onset. 
 
Neuropathology of the novel TBK1 p.Ile85del mutation  
Neuropathological examination of Case 2, carrying the novel p.Ile85del mutation, revealed severe 
lower motor neuronal loss in the anterior horns of the spinal cord.  The lower motor neurons of the 
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hypoglossal nucleus in the medulla were better preserved. The motor cortex similarly had very little 
change on conventional histology with rather mild microvacuolation of the underlying white matter.  
Conventional histology of the brainstem and midbrain was normal including a well-populated 
substantia nigra without evidence of neuronal loss.  There was no cerebellar atrophy and the 
Purkinje cell layer was well preserved. Conventional histopathology of the extra motor neocortices, 
hippocampus, deep grey structures and cerebellum was normal for the age of the patient.  
Immunohistochemistry for phosphorylated TDP-43 in the spinal cord highlighted skein-like inclusions 
in approximately 9% of lower motor neurons in the cervical and lumbar enlargements and granular, 
so-I;ﾉﾉWS さヮヴW-ｷﾐIﾉ┌ゲｷﾗﾐゲざ ｷﾐ デｴW ﾏWS┌ﾉﾉ;く OII;ゲｷﾗﾐ;ﾉ ｪﾉｷ;ﾉ I┞デﾗヮﾉ;ゲﾏｷI ｷﾐIﾉ┌ゲｷﾗﾐゲ ┘WヴW ;ﾉゲﾗ ﾗHゲWヴ┗WS 
in the anterior horns and corticospinal tracts (Figure 3). In all layers of the motor cortex, there was a 
moderate number of neuronal cytoplasmic inclusions together with a very small number of neurites 
(approximately 1 per spinal cord section). Glial cytoplasmic inclusions were quite numerous. This 
pattern best corresponds to FTLD-TDP type B pathology (30). Neuronal intranuclear inclusions were 
not present and there was no significant accentuation of TDP-43 pathology at the interface between 
the motor cortex and the underlying white matter. TDP-43 pathology was not present in extramotor 
regions (middle frontal gyrus, superior and middle temporal gyri and hippocampus).   
Immunohistochemistry for CD68 revealed a moderate microglial reaction with both ramified and 
amoeboid forms in the corticospinal tracts at all levels examined (spinal cord, medullary pyramids, 
cerebral peduncles, and white matter underlying the precentral gyrus) as well as the grey matter of 
the spinal cord anterior horns, medulla and motor cortex. 
Immunohistochemistry for hyper phosphorylated tau revealed low-level pathology in the form of 
neurofibrillary tangles and neuropil threads in the entorhinal cortex of moderate density in the inner 
and outer layers of the remnants of the entorhinal region, corresponding to Braak stage II by 
BrainNet Europe protocols (31). Tau pathology was otherwise absent from the motor cortex, 
occipitotemporal gyrus, superior and middle temporal gyri, motor cortex and spinal cord. 
Immunohistochemistry for TBK1 was performed in spinal cord to determine if there was any 
distinctive pathology associated with this TBK1 variant. In controls, there was moderate, diffuse 
staining of the neuropil that was greater in grey than white matter. The degree of motor neuron 
TBK1 expression ranged from strong to similar levels to that of the surrounding neuropil. There was 
no staining of glial nuclei or cell bodies. No differences were observed in the spinal cord of the 
mutant TBK1 case compared to the SALS and neurologically normal controls (Figure 4, a&b).   
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Immunohistochemistry for IRF3 was also performed on spinal cord, to see if there were changes in 
expression and/or location of this protein which acts downstream of TBK1 in the innate immune 
response. Since TBK1 phosphorylates IRF3 resulting in translocation of IRF3 to the nucleus, we 
hypothesised that any loss of function TBK1 would result in less phosphorylation of IRF3 and less 
nuclear localisation. In controls, expression of IRF3 was variable. The majority of the protein was in 
the grey matter neuropil, with virtually no neuronal staining. A number of glia in both grey and white 
matter labelled strongly for IRF3, with straining primarily in the glial cytoplasm, as most nuclei were 
negative for IRF3. However, the degree of staining was variable, such that other glia did not seem to 
express IRF3. Again, no differences were observed between mutant TBK1, SALS and control spinal 
cord (Figure 4, c&d). This suggests that the TBK1 loss of function mutation did not have any negative 
effect on IRF3 expression or localisation.  
 
DISCUSSION 
The mutation screening of TBK1 in 290 ALS cases identified 4 variants (one nonsense, two in frame 
deletions and one missense) that were predicted to be pathogenic and associated with the disease, 
providing a frequency for TBK1 mutations in our cohort of 1.38. One of the in-frame deletions, 
p.Ile85del, is a novel mutation, not previously reported in the literature or in online databases. A 
further three missense variants were identified, though the pathogenicity of two of these 
(p.Lys291Glu, p.His322Tyr) is uncertain. Unfortunately, no further biosamples are available from these 
patients to investigate functional implications of these variants. Fifteen additional variants which 
caused synonymous substitutions or occurred in non-coding regions were also identified, though 
these were not considered to be pathogenic.  
 
Pathogenic Variants 
Of the four TBK1-ALS cases, the age of onset ranged from 46 to 61 years of age. In the three deceased 
patients, the range of disease duration was two to five years, though one patient with a nonsense 
mutation is alive after having the disease for over 7 years. This variability is consistent with the clinical 
heterogeneity of cohorts within other studies of TBK1 mutation carriers. In one large study, loss of 
function mutations were associated with a range of onset from 48-78 years and a disease duration of 
6-136 months, whilst perhaps surprisingly, functional missense mutations were associated with an 
earlier onset of 34-57 years (6). Our case with a predicted functional missense mutation, p.Gln565Pro, 
had an age of onset of 51 years, though the youngest onset in our cohort was at 46 years, with the 
loss of function mutation p.Glu2Ter, which is younger than the range cited in the earlier study. 
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There does not appear to be a clear phenotype associated with TBK1 mutations when compared to 
other genetic and sporadic ALS cases. Equally, there is no clear pattern with regard to specific 
mutations being associated with clinical features or disease. In the case of the p.Glu2Ter, this mutation 
has been reported in three other studies (Supplementary Table 3) (4, 13, 17). Whilst limited 
information was available in one paper - the patient had ALS as did our Case 1 に in a second report the 
patient had sporadic behavioural variant FTD (bvFTD), with an onset at 56 years and a disease duration 
of 4 years. The third case reported was also of an ALS patient, with limb-onset disease at 60 years. 
Only two other cases of Gln565Pro have been reported (4, 17), both of which were ALS. Again, limited 
information is available on one, however, the other was very similar to our Case 4, with limb onset 
familial ALS and a disease duration of 3 years. 
The pGlu643del mutation has previously been found in 8 independent cases with either ALS or 
dementia (4, 5, 13) as well as within a large family from Belgium, presenting with both ALS and 
dementia (13). Interestingly, where the type of dementia has been documented, this is predominantly 
bvFTD, though one case with primary progressive aphasia (PPA) has also been described, which 
correlates with Case 3 presenting with word finding difficulties prior to motor symptoms. Thus, 
mutations in TBK1 appear to underlie a range of dementia phenotypes as well as ALS, with variability 
in age and site of onset. 
 
Neuropathology 
The pathology found in the novel p.Ile85del patient is representative of classical ALS-type TDP-43 
proteinopathy in addition to Type B FTLD-TDP proteinopathy. The FTLD pathology is consistent with 
the majority of neuropathology reports so far describing TBK1 mutation carriers with either FTD-MND 
or pure FTD phenotypes (Table 4) (5-7, 9, 13). The exception to this is the neuropathology found by 
Pottier and colleagues in a study of FTD cases, who have described Type A FTLD-TDP pathology in an 
individual with FTLD carrying a TBK1/OPTN double mutant and an second FTLD individual with a TBK1 
missense mutation (9). In the same study, two TBK1 missense mutation carriers with a pathological 
diagnosis of FTLD-MND showed Type B FTLD-TDP pathology, whilst an FTLD case with a double OPTN 
mutation displayed Type A, suggestive that the OPTN mutation could be driving the Type A pathology 
in the double mutant.  
 
The degree of motor system pathology of cases reported so far is variable. Thus the two cases of 
Pottier and colleagues lack brainstem motor neuron pathology (the motor cortex was not commented 
on and spinal cord tissue was unavailable) (9). ALS patient DR1124 (p.Ser518Leufs*32) reported by 
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Gijselinck and colleagues had TDP-43 proteinopathy of brainstem and spinal cord lower motor 
neurons and 2 out of the 3 patients with TBK1 mutations (13) and autopsy data in the van der Zee 
study showed the TBK1 mutants had motor TDP-43 proteinopathy (6). 
 
Several previous reports have performed immunohistochemistry with TBK1 and found variable 
cytoplasmic neuronal staining, consistent with our findings. To determine whether loss of TBK1 
function had an effect on the downstream proteins in the immune pathway, we also stained for IRF3. 
However, no changes in expression or localisation of this protein were seen associated with the 
p.Ile85del TBK1 mutation compared to controls, suggesting that disruption of the IRF3-related innate 
immunity signalling pathway is not effected by the TBK1 loss of function mutation.  
 
In summary, screening of the TBK1 gene in a cohort of patients from the North of England identified 
four pathogenic variants, accounting for a frequency for TBK1 mutations of 1.38% of this ALS 
population. We identified a novel loss of function mutation, p.Ile85del, and neuropathological 
characterisation showed this mutation was associated with classical ALS and Type B FTLD-TDP 
pathology. No changes in expression or localisation of TBK1 or IRF3, a downstream effector of TBK1, 
were detected between the p.Ile85del case and other SALS or control cases. Thus, within this cohort, 
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Figure 1: Predicted pathogenic TBK1 variants identified in the cohort of ALS patients from Northern 
England. 
  
Figure 2: Novel TBK1 exon 4 p.Ile85del in frame deletion a. Representative reverse primer 
chromatogram b. Predicted effect of exon 4 p.Ile85Del (blue) on TBK1 protein structure (red/yellow) 
and c. in depth, showing changes in polar bonds.  
 
Figure 3: Neuropathology of case 2 with a novel p.Ile85del. Immunohistochemistry for phosphorylated 
TDP-43 in the ventral horns of the spinal cord reveals neuronal (a, arrow, bar = 10µm) and glial (b, 
arrow, bar = 10µm) cytoplasmic inclusions.  Immunohistochemistry for the microglial marker reveals 
a mild reaction that is more prominent in the corticospinal tracts and ventral horns (c, high 
magnification, arrow highlights an amoeboid microglial cell, bar = 25µm; d, low magnification, dotted 
outline, bar = 1µm). Immunohistochemistry for phosphorylated TDP-43 in the motor cortex reveals 
both neuronal (e, arrow) and glial (f, arrow) cytoplasmic inclusions but a lack of TDP-43 positive 
neurites (bar = 10µm) 
 
Figure 4: Immunohistochemistry for TBK1 and IRF3 protein. Staining of TBK1 in a representative 
control (a) and patient with TBK1 mutation (b) in the spinal cord anterior horn and adjacent white 
matter shows neuropil expression is greater in the grey matter (GM) than white matter (WM).  
Neuronal cytoplasmic staining (arrow, a & b) is greater than neuropil staining.  Bar = 250µm. 
Immunohistochemistry for IRF3 protein in a representative control (c) and patient with TBK1 mutation 
(d) in the spinal cord anterior horn shows both nuclear (open arrow) and cytoplasmic (closed arrow) 
glial expression. Expression is variable, such that some glia are positive, while others are negative (grey 






Table 1: Antibodies used for Neuropathological Examination 
 









Phosphorylated tau AT8 (ThermoFisher) Pressure cooker 
pH6 
1:200 
CD68 Abcam, PGM1, ab783 Pressure cooker 
pH6 
1:100 
TBK1  Abcam ab109735 Pressure cooker 
pH9 
1:3000 







Table 2: TBK1 coding variants identified and bioinformatic analyses performed to determine functional effects of non-synonymous coding changes. Shaded grey = predicted pathogenic 
variants. Bold = novel mutation. All = frequency in all populations; Eur = European (non-Finnish). N/A = not applicable; NR = not reported in database 














SIFT Allele Frequencies ClinVar References 
 gnomAD 









1 2 Nonsense c.4C>T p.Glu2Ter Disease 
causing 
N/A N/A NR NR NR NR (4, 13, 17) 






N/A N/A NR NR NR NR NOVEL 
MUTATION 






N/A N/A 0.00001102/ 
0.00002389 
3 alleles 
NR NR NR (4, 5, 13) 

















Reported in ALS & 
controls  
















significance /  
Likely benign 
Reported in ALS & 
controls 














Benign Reported in ALS & 
controls   
















Table 3: Clinical features of ALS patients with pathogenic TBK1 mutations.  
*Maternal grandmother had a form of dementia; **Patient alive 7.75 years after symptom onset; #Cognitive 
impairment began at 61 years with word finding difficulties, whilst ALS symptoms began aged 64 years. 
 
Case Amino acid 
change 
Phenotype Age at Onset 
(years) 
Duration of illness 
(months) 
Cognitive change 
1 p.Glu2Ter (F)ALS* 46 92** No 
2 p.85delIle SALS 59 57 No 
3 p.Glu643del FALS 61 (64)# 24 Slow information 
processing, irritability 
and emotional lability 






Table 4: Neuropathological features of TBK1 mutation carriers. The OPTN double mutant published with TBK1 
mutant associated pathology by Pottier et al, 2015 is included for completeness. Both clinical diagnosis (and 
pathological diagnosis in parentheses) are provided where available. OPTN ﾏ┌デ;デｷﾗﾐゲ ｷﾐ ｷデ;ﾉｷIゲく AD Э Aﾉ┣ｴWｷﾏWヴげゲ 
disease; FTD = frontotemporal dementia; bvFTD = behavioural variant FTD; FTLD = frontotemporal lobar 
dementia; agPPA = progressive non fluent/agrammatic variant of primary progressive aplasia. 













66 Type B TDP-43 and p62 positive perinuclear 
neuronal inclusions temporal lobe. 






50 Type B Moderate TDP-43 and p62 positive 
neuronal cytoplasmic inclusions (NCI), 
short dystrophic neurites, no 
intraneuronal intranuclear inclusions. 
Motor system not described.  
(13) 
p.Ser518Leufs*32 Bulbar onset 
ALS 
(ALS) 
64 Type B Upper and lower motor neuron loss, 
TDP-43 in motor neurons, variable 
cytoplasmic neuronal staining with 
TBK1, no co-localisation with TDP-43 
NCIs 
(13) 
p.Thr79del Bulbar onset 
ALS + bvFTD 
(FTLD-ALS) 
58 Type B Neuronal loss, reactive astrogliosis and 
microglial activation, TDP-43 positive 
NCI, isolated dystrophic neurites, CD68 
positive macrophages; also argyrophilic 
grain pathology (AgD) characterised by 
hyperphosphorylated tau (AT8).  
Involvement of both motor (anterior 
horn and brainstem motor nuclei) as 
well as extra motor deep grey, 
neocortical and mesial temporal 




63  TDP-43 positive inclusions. (6) 
p.Ala417* bvFTD 
(FTLD) 








70 Type A Mild cortical atrophy, p62 and TDP-43 
pathology in cortical grey matter, no 
OPTN or TBK1 pathology, no neuronal 









72 Type A Severe focal cortical atrophy in frontal 
lobe, many neuronal and glial 
cytoplasmic and intranuclear 
inlcusions, no neuronal loss in motor 





84 Type B No further information available (9) 
p.Leu306Ile FTD-ALS 
(FTLD-MND) 
72 Type B No further information available (9) 
p.Lys401Glu AD 
(FTLD) 
90 Type A No further information available (9) 
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Figure 2: Novel TBK1 exon 4 p.Ile85del in frame deletion a. Representative reverse primer chromatogram b. 
Predicted effect of exon 4 p.Ile85Del (blue) on TBK1 protein structure (red/yellow) and c. in depth, showing changes 





Figure 3: Neuropathology of case 2 with a novel p.Ile85del. Immunohistochemistry for phosphorylated TDP-43 in the 
ventral horns of the spinal cord reveals neuronal (a, arrow, bar = 10µm) and glial (b, arrow, bar = 10µm) cytoplasmic 
inclusions.  Immunohistochemistry for the microglial marker reveals a mild reaction that is more prominent in the 
corticospinal tracts and ventral horns (c, high magnification, arrow highlights an amoeboid microglial cell, bar = 25µm; 
d, low magnification, dotted outline, bar = 1µm). Immunohistochemistry for phosphorylated TDP-43 in the motor 
cortex reveals both neuronal (e, arrow) and glial (f, arrow) cytoplasmic inclusions but a lack of TDP-43 positive neurites 





Figure 4: Immunohistochemistry for TBK1 and IRF3 protein. Staining of TBK1 in a representative control (a) and patient with TBK1 mutation (b) in the spinal cord anterior horn 
and adjacent white matter shows neuropil expression is greater in the grey matter (GM) than white matter (WM).  Neuronal cytoplasmic staining (arrow, a & b) is greater 
than neuropil staining.  Bar = 250µm. Immunohistochemistry for IRF3 protein in a representative control (c) and patient with TBK1 mutation (d) in the spinal cord anterior 
horn shows both nuclear (open arrow) and cytoplasmic (closed arrow) glial expression. Expression is variable, such that some glia are positive, while others are negative (grey 





Supplementary Table 1: PCR primers used to amplify TBK1 exons. All PCR reactions were performed as follows: initial 
denaturation of 95°C for 5min, followed by 35 cycles of 95°C for 30sec, annealing at 60°C for 30sec, and 72°C for 45sec, followed 
by a final elongation step at 72°C for 10mins. 




2 CAGATCCGTCTCTCCAGAGGAA ACCTGTGCCACCACTGGGTA 565 (21) 
3 TCCCTGTGCCTAAAAGATGC AGGTTCTATTTCTTGACTCGTAACT 327 Primer blast 
4 CACCCGGCCGGAAGATATTA TGGGCTGTCTTTTCACTTACCTG 525 (21) 
5 TCAATGAATTTGAGACATGCACAC TTGGCTGACCAATTACCCAATTA 334 (21) 
6 TTTGAGGAGGGAGGGGAAGA TGGGCCAAAGACTGAATACCA 564 (21) 
7 TGGATCCTGTGAGCATCAATCA AAGGTCCTGAGCATGATCCCTA 543 (21) 
8 GCCCCAGAGTTTGAGACTGC TGGTGAAGCTGAGGCATCTTT 580 (21) 
9 GAAATGGATGTTGTTGCACTCATT CAGGGTCCCACACTGTCTCC 532 (21) 
10 AAAGAGAAGCATTGGACTCATTGTG TTTGGTGCTAATTGTGGTATAGGG 692 (21) 
11 TCTCTCCATTGAGATAGTGCATGTT TCAATGATGGGGCAAGGTCT 361 (21) 
12 ATACATCAGGATCACAGAAATGCT ATGCCATATTGTGCCAAGGAT 370 Primer blast 
13 ACAATCTGCTGGCTTATAGACTTTG AGTGCCAGCAAAGGAATAGGT 283 Primer blast 
14-15 GACTTTGTTGGGACTGTGAGT AGCTACCCTTACAGATATACCAAAT 459 Primer blast 
16 TTGCCCAATCTTCCCATTTC GGGAGCAGATGTGTGAACCTC 486 (21) 
17-18 GCCACAACAATCATTATAGGAAAGA TTGGTGGGTGGAACTGAATG 532 (21) 
19-20 TTAAAAGCTGTAACACTTGATGTCAGA TGACCCTTTACCACTGCTGAAT 597 (21) 






















g.64875680A>G c.871A>G p.Lys291Glu rs34774243 1 0.0001394 0.0002653 
g.64875773C>T c.964C>T p.His322Tyr rs145905497 1 0.0004286 0.0002960 
Exon 12 g.64882317T>C c.1391T>C p.Val464Ala rs35635889 13 0.01358 0.01990 
Exon 2 
Synonymous 
g.64849716T>C c.964C>T p.Asp22Asp rs41292019 38 0.03246 0.04653 
Exon 8 g.64875787T>A c.978T>A p.Ile326Ile rs7486100 223 0.4730 0.5559 
Exon 9 g.64878200C>T c.1110C>T p.Phe370Phe rs143590388 1 0.001464 0.002371 
Intron 7-8 
Non coding 
g.64874102A>C  - rs7303577 59 0.1474 0.1196 
g.64875468C>G - - - 1 - - 
Intron 8-9 g.64878021A>C - - - 2 - - 
Intron 9-10 g.64879165T>C - - rs11175411 34 0.1475 0.1093 
Intron 10-11 g.64879436G>T - - rs41292023 40 0.1643 0.1201 
Intron 11-12 g.64882257delT  - rs201728462 2 0.006802 0.008970 
Intron 12-13 g.64883761C>A - - rs10878177 161 0.2240  0.3039 
Intron 14-15 g.64889417T>C - - rs149784987 2 0.00184 0.00319 
Intron 15-16 g.64889915A>C - - rs117570362 3 0.0092 0.0133 
Intron 18-19 g.64891093G>A - - rs746426213 1 0.0001 0.0001 
Intron 20-21 
g.64894932dup - - rs773423523 1 0.0002 0.0003 
g.64895099G>A - - rs41292027 6 0.01363 0.00937 
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Supplementary Table 3: Literature summary of clinical data of patients with the 3 previously reported pathogenic TBK1 
mutations. Ages and survival time in years. *Individuals all members of same family 









p.Glu2Ter         
Case 1 ALS (F)ALS M Limb 46 - 8+ No 
(4) ALS - - - - - - - 
(13) FTD Sporadic F - 56 60 4 bvFTD 
(17) ALS Familial F Spinal 60 - - - 
         
p.Glu643del         
Case 3 ALS Familial M Limb 61 66 5 Word finding difficulties, 
emotional lability 
(5) ALS Sporadic M - - - - - 
(5) ALS Sporadic M Spinal - - - - 
(13) Dementia Familial* F - 71 81 10 Dementia 
(13) Dementia Familial* F - 86 90 4 Dementia 
(13) ALS Familial* M Spinal 69 72 3 - 
(13) FTD Familial* M - 69 75 6 bvFTD 
(13) Dementia Familial* M - 70 73 3 Dementia 
(13) FTD Familial* F - 61 74 13 bvFTD 
(13) Dementia Familial* F - 63 69 6 Dementia 
(13) FTD-ALS Familial* F Spinal 62 74 11 bvFTD 
(13) Dementia Familial* F - 73 84 11 Dementia 
(13) FTD Familial F - 64 - >9 bvFTD 
(13) FTD Familial M - 70 - >6 PPA 
(13) FTD Sporadic F - 69 - >7 bvFTD 
(13) ALS Sporadic M - 63 66 3 - 
(13) ALS Familial M Bulbar 41 41 <1 - 
(4) ALS - - - - - - - 
         
p.Gln565Pro         
Case 4 ALS Familial F Limb 51 55 4 Emotionally labile 
(4) ALS - - - - - - - 
(17) ALS Familial F Limb 50 53 3 - 
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Supplementary Figure 1: TBK1 exon 18 p.Glu643del in frame deletion a. Representative forward 
primer chromatogram highlighting area of deletion b. Predicted effect of exon 18 p.Glu643del 








Supplementary Figure 2: TBK1 exon 15 p.Gln565Pro missense mutation a. Representative forward 
primer chromatogram b. Predicted TBK1 whole protein structure (red/yellow) with area of missense 
mutation (blue) c. In depth reference TBK1 protein structure (blue/green) with polar bonds, 
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